Led · Series A · Jun 2026

Arpio provides cloud-native recovery automation that enables enterprises to replicate, test, and recover cloud workloads automatically, aiming to replace manual, legacy disaster recovery approaches. Its platform allows customers to test recovery capabilities in minutes and outside maintenance windows to ensure recovery environments function properly. The company is led by CEO Doug Neumann and is headquartered in Durham, NC. Arpio plans to deepen integrations with AWS and Microsoft Azure and expand support to Google Cloud and other AI-native services. Financially, Arpio has just completed a $15M Series A round to fund this product and market expansion.

Participated · Seed · Feb 2026

Stanhope AI is developing a brain-inspired system called “Active Inference,” which lets machines learn and adapt on the fly rather than depending on large, static datasets like those used by current LLMs. This adaptive capability targets mission-critical applications across autonomous systems, defence technology, industrial automation, and embedded devices where efficiency and reliability are paramount. The company is led by CEO Professor Rosalyn Moran alongside Professor Karl Friston, both noted researchers in computational neuroscience. With its technology, Stanhope AI aims to bridge the gap between biological cognition and machine learning, offering more efficient and resilient AI solutions. The startup plans to use newly secured capital to accelerate product development and scale operations. To date, its external financing totals $8 million, and no additional operating metrics such as revenue or user figures have been disclosed.

Led · Series A · Feb 2026

Founded in 2021 and based in Boulder, Colorado, RADICL Defense has built an autonomous virtual security operations center (vSOC) tailored for small and mid-sized businesses operating in regulated or high-risk environments such as the defense industrial base and critical infrastructure. The company’s cybersecurity-as-a-service platform blends AI-driven “agentic operators” with human expertise to identify, assess, and respond to cyberattacks at machine speed, providing nation-state-level defense-in-depth and managed compliance. RADICL’s modular offerings unify workflows for agentic and human operators, the customer, and managed service providers, aiming to make SOC operations increasingly autonomous and software-led. Its vSOC helps SMBs improve both compliance and security posture in the face of emerging automated, AI-powered threats. The firm positions itself as a proactive answer to the growing “AI-enabled threat tsunami” that disproportionately affects resource-constrained organizations. With total funding now at $42 million, RADICL plans to accelerate AI-native vSOC development, launch new products, and drive broader market adoption.

Led · Seed · Jan 2026

Dam Secure develops an AI-native security platform aimed at enabling enterprises to identify and mitigate the new classes of vulnerabilities introduced by rapid adoption of AI-assisted coding products. The system is designed to give security teams continuous visibility into AI-generated code, detect potential threats early, and enforce policy controls before issues reach production. Founded by Patrick Collins and Simon Harloff, the company operates out of Sydney with a presence in San Francisco to stay close to both Asia-Pacific and U.S. customers. Management plans to use its newly raised seed capital to accelerate product development, deepen threat-detection capabilities, and build out an enterprise sales organization during 2026. While still in the seed stage, Dam Secure intends to scale go-to-market operations aggressively to capture early demand from security-conscious organizations adopting AI tooling. No operating metrics such as revenue or user counts were disclosed in the article, underscoring the company’s early-stage status. The fresh funding positions the firm to reach key technical milestones and validate market fit before pursuing larger growth rounds.

Participated · Seed · Nov 2025

Hermes Biosciences is a life-science tools startup focused on turning extracellular vesicles (EVs) into a practical and standardized resource for precision medicine. Its flagship product is a benchtop, fully automated instrument designed to isolate EVs at higher yield and purity than existing approaches, enabling more reliable downstream analysis for clinical researchers in academia, biopharma, and diagnostic laboratories. The company intends to launch its first commercial instrument in 2026, offering a scalable and hands-off workflow that can be integrated into regulated clinical environments. By improving EV capture, Hermes aims to advance biomarker discovery, non-invasive diagnostics, and targeted therapeutics. The San Francisco-based team is still pre-revenue, using newly secured capital to complete product development, expand manufacturing capabilities, and build out sales channels. The firm’s initial $6 million seed financing may grow as additional investors are engaged, giving Hermes runway to reach its commercialization milestones.